Lannett Co. Given “Buy” Rating at Oppenheimer (LCI)
Lannett Co. (NYSE:LCI)‘s stock had its “buy” rating reiterated by stock analysts at Oppenheimer in a report issued on Thursday, Stock Ratings Network reports. They currently have a $20.00 price objective on the stock. Oppenheimer’s price target points to a potential upside of 5.43% from the company’s current price.
A number of other analysts have also recently weighed in on LCI. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Lannett Co. in a research note to investors on Thursday. They now have a $18.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Lannett Co. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, October 4th. They now have a $23.00 price target on the stock. Finally, analysts at Needham & Company downgraded shares of Lannett Co. from a “buy” rating to a “hold” rating in a research note to investors on Friday, October 4th.
Lannett Co. (NYSE:LCI) traded up 5.62% during mid-day trading on Thursday, hitting $18.97. The stock had a trading volume of 565,338 shares. Lannett Co. has a 52-week low of $3.93 and a 52-week high of $23.42. The stock’s 50-day moving average is $16.94 and its 200-day moving average is $13.21. The company has a market cap of $576.5 million and a price-to-earnings ratio of 39.04.
Lannett Co. (NYSE:LCI) last announced its earnings results on Tuesday, September 10th. The company reported $0.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.07 by $0.05. The company had revenue of $40.20 million for the quarter, compared to the consensus estimate of $37.89 million. During the same quarter last year, the company posted $0.05 earnings per share. Lannett Co.’s revenue was up 12.6% compared to the same quarter last year. Analysts expect that Lannett Co. will post $0.55 EPS for the current fiscal year.
Lannett Company, Inc is engaged in developing, manufacturing, marketing and distributing generic versions of branded pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.